TYK2 and COVID-19: We finally observe that some genomic regions conferring a higher risk for severe COVID-19 might be protective for diseases that partially share pathomechanisms with COVID-19, or vice versa, with possible implications for drug development programs, such as TYK2-inhibitors that may increase the risk for severe COVID-19.